^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Ariely (adebrelimab)
i
Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
6d
SHR-1316-SCLC-LN-001: Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Small Cell Lung Cancer (clinicaltrials.gov)
P=N/A, N=38, Recruiting, Yunpeng Liu | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
|
PD-L1 expression • CXCL8 expression • IL6 expression
|
cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
6d
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
P2, N=32, Not yet recruiting, Fudan University | Initiation date: Jul 2024 --> Dec 2024
Trial initiation date • Metastases
|
Ariely (adebrelimab) • tizetatug rezetecan (SHR-A1921)
8d
HAICI: Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma (clinicaltrials.gov)
P1/2, N=10, Not yet recruiting, Zhejiang Cancer Hospital
New P1/2 trial
|
5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • leucovorin calcium • Ariely (adebrelimab)
8d
HAIBrave-001: HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=78, Recruiting, Sun Yat-sen University
New P2 trial • Metastases
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Ariely (adebrelimab)
10d
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=40, Not yet recruiting, Guangdong Provincial People's Hospital
New P1 trial • Combination therapy
|
Ariely (adebrelimab)
10d
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC (clinicaltrials.gov)
P2, N=35, Recruiting, Beijing Chest Hospital, Capital Medical University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
Enrollment open • Trial completion date • Trial primary completion date
|
carboplatin • albumin-bound paclitaxel • Ariely (adebrelimab)
16d
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis (clinicaltrials.gov)
P2, N=30, Recruiting, Beijing 302 Hospital | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Oct 2024
Enrollment open • Trial initiation date
|
AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
1m
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov)
P1/2, N=876, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1/2 trial • Combination therapy
|
Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium • CS1002 (ipilimumab biosimilar) • Ariely (adebrelimab)
1m
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=350, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
trastuzumab rezetecan (SHR-A1811) • Ariely (adebrelimab) • SHR-A2009
1m
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (clinicaltrials.gov)
P1, N=448, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Combination therapy
|
Focus V (anlotinib) • epirubicin • Ariely (adebrelimab) • GSK5764227
1m
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
P2, N=33, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Mar 2024 --> Dec 2023
Trial initiation date
|
gemcitabine • Lenvima (lenvatinib) • oxaliplatin • Ariely (adebrelimab)
1m
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
P1/2, N=90, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
CS1002 (ipilimumab biosimilar) • SHR-A2102 • Ariely (adebrelimab)
1m
SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov)
P2, N=200, Not yet recruiting, Peking University Shenzhen Hospital
New P2 trial
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • gemcitabine • Rozlytrek (entrectinib) • imatinib • 5-fluorouracil • Tyvyt (sintilimab) • Alecensa (alectinib) • Nerlynx (neratinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Irene (pyrotinib) • Balversa (erdafitinib) • albumin-bound paclitaxel • irinotecan • Orpathys (savolitinib) • epirubicin • vinorelbine tartrate • Partruvix (pamiparib) • Epkinly (epcoritamab-bysp) • Hetronifly (serplulimab) • Enweida (envafolimab) • Vumon (teniposide) • Ariely (adebrelimab)
1m
SHR-8068-301: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P3, N=560, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab)
1m
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC (clinicaltrials.gov)
P2, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
New P2 trial
|
docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Ariely (adebrelimab) • Pegylated rhG-CSF (mecapegfilgrastim)
1m
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=124, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
SHR-A2102 • Ariely (adebrelimab)
2ms
Prospective and exploratory clinical study on the efficacy and safety of Adebrelimab combined with chemotherapy as first-line treatment for unresectable locally advanced, recurrent, or metastatic neuroendocrine carcinoma of the digestive tract (ChiCTR2400088905)
P=N/A, N=20, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
New trial • Metastases
|
cisplatin • carboplatin • etoposide IV • Ariely (adebrelimab)
2ms
Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: a single-arm, real-world study (ChiCTR2400091083)
P4, N=78, Not yet recruiting, The Sixth People’s Hospital of Shenyang; The Sixth People’s Hospital of Shenyang
New P4 trial • Real-world evidence • Real-world
|
AFP (Alpha-fetoprotein) • CRP (C-reactive protein)
|
Ariely (adebrelimab)
2ms
A multicenter, open-label, phase Ⅲ randomized controlled trial evaluating the efficacy and safety of adebrelimab in combination with chemotherapy and low-dose radiotherapy (LDRT) as first-line treatment for extensive-stage small cell lung cancer (SCLC) (ChiCTR2400090673)
P3, N=202, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P3 trial • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Ariely (adebrelimab)
2ms
Drug-eluting Beads Transcatheter Arterial Chemoembolization Plus Adebrelimab and Apatinib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (TACT-01): A Single-arm, Exploratory Trial (ChiCTR2400090184)
P2, N=31, Not yet recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
AiTan (rivoceranib) • Ariely (adebrelimab)
2ms
To evaluate the efficacy and safety of NALIRIFOX combined with adbelimumab in the first-line treatment of unresectable locally advanced or metastatic biliary tract malignancies (ChiCTR2400089696)
P2, N=27, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P2 trial • Metastases
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Ariely (adebrelimab)
2ms
Adebrelimab plus Chidamide in combination with Gemcitabine in patients with advanced squamous-cell non-small-cell lung cancer who previously progressed during or after treatment of PD-1 inhibitors (L-Aunching/SCOG-L003): A prospective, single-arm, exploratory trial (ChiCTR2400090083)
P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New P2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
|
gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)
2ms
Adebrelimab combined with irinotecan liposome, 5-fluorouracil, calcium folinate ± lenvatinib in first-line treatment of advanced intrahepatic cholangiocarcinoma:a prospective clinical study (ChiCTR2400089273)
P2, N=68, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
2ms
Efficacy and safety of adebrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a randomized controlled open-label phase II study (ChiCTR2400080080)
P2, N=36, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University | Not yet recruiting --> Recruiting
Enrollment open
|
Lenvima (lenvatinib) • Ariely (adebrelimab)
2ms
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study (clinicaltrials.gov)
P2, N=80, Recruiting, Tang-Du Hospital
New P2 trial • Metastases
|
cisplatin • albumin-bound paclitaxel • Ariely (adebrelimab)
2ms
SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study. (PubMed, Front Immunol)
This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.
Clinical protocol • P1/2 data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
|
MSI (Microsatellite instability)
|
Avastin (bevacizumab) • Airuituo (bevacizumab biosimilar) • Ariely (adebrelimab)
2ms
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (clinicaltrials.gov)
P3, N=400, Recruiting, Fudan University | Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2022 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Ariely (adebrelimab)
2ms
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC (clinicaltrials.gov)
P2, N=68, Not yet recruiting, Harbin Medical University
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
2ms
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
P1/2, N=90, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial • Combination therapy • Metastases
|
SHR-A2102 • Ariely (adebrelimab)
2ms
SHR-A1811-1316: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer (clinicaltrials.gov)
P2, N=93, Recruiting, Shengjing Hospital | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Aug 2024
Enrollment open • Trial initiation date • Combination therapy
|
trastuzumab rezetecan (SHR-A1811) • Ariely (adebrelimab)
3ms
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
P=N/A, N=14, Not yet recruiting, Fudan University
New trial
|
carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Ariely (adebrelimab)
3ms
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P3, N=560, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P3 trial
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab)
3ms
A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. (clinicaltrials.gov)
P2, N=49, Not yet recruiting, Shanghai Zhongshan Hospital
New P2 trial
|
Ariely (adebrelimab) • HRS-4642
3ms
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=43, Not yet recruiting, Fujian Cancer Hospital
New P2 trial
|
AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
3ms
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer. (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Ningbo Medical Center Lihuili Hospital
New trial • Metastases
|
Fruzaqla (fruquintinib) • Ariely (adebrelimab)
3ms
Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC (clinicaltrials.gov)
P3, N=202, Not yet recruiting, Sichuan University
New P3 trial
|
Ariely (adebrelimab)
3ms
ACAC: Adebrelimab Combined With Capecitabine for Adjuvant Therapy in Cholangiocarcinoma With High-risk Recurrence Post-surgery (clinicaltrials.gov)
P2, N=122, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
New P2 trial
|
Tecentriq (atezolizumab) • capecitabine • Ariely (adebrelimab)
3ms
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=124, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial • Combination therapy • Metastases
|
SHR-A2102 • Ariely (adebrelimab)
3ms
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=37, Not yet recruiting, Fujian Cancer Hospital
New P2 trial • IO biomarker
|
HRD (Homologous Recombination Deficiency)
|
PD-L1 expression • HRD
|
albumin-bound paclitaxel • AiRuiYi (fluzoparib) • Ariely (adebrelimab)
3ms
Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP regimen) for unresectable advanced biliary tract cancer (ChiCTR2400087017)
P4, N=144, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
New P4 trial • Metastases
|
cisplatin • gemcitabine • Ariely (adebrelimab)
3ms
Adebrelimab plus chemotherapy as first-line treatment in advanced first-line non-small cell lung cancer:a single arm ,phase 2 trial. (ChiCTR2400087166)
P4, N=42, Not yet recruiting, Taihe hospital,Affiliated hospital of hubei university of medicine; Taihe hospital
New P4 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK translocation
|
Ariely (adebrelimab)
3ms
Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer (ChiCTR2400087077)
P4, N=114, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
New P4 trial
|
AiTan (rivoceranib) • Ariely (adebrelimab)
Share via
